NovelMed Therapeutics, Inc. is an American private company located in Cleveland, OH. The firm provides pharmaceutical research and development services. It was founded in 2003. Rekha Bansal is the current CEO of the firm.\nThe company says this about itself: As a clinical-stage biopharmaceutical company, we are committed to innovating and developing novel biologics for the treatment of rare (orphan) diseases. Our goal is to develop an alternative pathway specific drug that can treat a multitude of rare diseases and provide patients with low-cost treatment. NovelMed has created a strong portfolio of intellectual property with broad applications to rare and common diseases. This includes the use of NM8074 as a treatment for a range of complement-mediated disorders related to uncontrolled activation of the AP. As part of its antibody platform, NovelMed's portfolio also includes humanized antibodies to C3b and Factor P (Properdin) that also block the formation of C3/C5 convertases. NovelMed is currently seeking licensing, partnership, and acquisition opportunities to drive its antibody development through Phase III and approval in multiple rare disease indications.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts.

Mars, Inc. engages in the production of confectionery and animal food products. Its brands include M&M?s, Snickers, Twix, Milky Way, Dove, Pedigree, Whiskas, Extra, Skittles, Uncle Ben's, and Cocoavia. The company was founded by Franklin Clarence Mars in 1911 and is headquartered in McLean, VA.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Huiyu Kangcheng (Hangzhou) Pharmaceutical Technology Co., Ltd., established on 2018-11-29, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Biochemical product technology research and development;Chemical product sales(No licensed chemical products)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:pharmaceutical production;Pharmaceutical commissioned production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines. It was created with the goal of applying Nanosponge Technology to treat and prevent diseases. It aims to employ innovative biomimetic nanomedicines to address serious diseases with a high unmet medical need. The company’s initial primary focus is on autoimmune and inflammatory diseases and difficult to treat infectious diseases. Additionally, Cellics is seeking to develop best-in-class vaccines for various diseases. The company is currently on schedule to advance its lead product candidate CTI-005 to human clinical trials for the treatment of bacterial pneumonia. It is the passion and goal of Cellics to use advanced technology to help human beings live healthier and longer lives. The company was founded in 2014 and is headquartered in San Diego, California.

Liminal BioSciences Ltd., part of Liminal R&D BioSciences, Inc., is a British company located in Comberton involved in biological products, except diagnostic substances. The firm was founded in 2015.

Laboratoire Francais du Fractionnement et des Biotechnologies SA provides plasma-derived medicinal products. It undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The firm's products include albumin and immunoglobulin. It also offers products for rare pathologies. The company was founded in 1994 and is headquartered in Les Ulis, France.

Chongming Bird Health Industry (Jiangsu) Co., Ltd., established on 2017-01-05, Business scope includes toilet culture research,to promote,comminicate;account Serive;Toilet Education Curriculum Development;mobile toilet,Eco-friendly toilet,Prefabricated toilet and mobile board room,Sanitation equipment,Green facilities,Garbage sorting equipment,Research and development of sewage treatment equipment,design,Production,Install,lease,Sales,Maintenance and after-sales service;Public toilet construction project;Steel structure engineering,Electromyography,Environmental Engineering;Integrated transformation of urban public toilets,operate,manage,Cleaning service;Septic tank equipment,Septic tank equipment,bathroom,sanitary ware,sanitary ware,cleaning supplies,paper products,building materials,Hardware,Sales of instrumentation;sanitation,Technology development in the field of environmental protection,Technical Services,technical consulting,technology transfer;Import and export business of goods and technology.(The law in the aforementioned business items,Permission to operate under administrative regulations,restricted operation,Except for prohibited operations);Refrigeration,Air Conditioning Equipment Manufacturing;Professional cleaning,to clean,Disinfection service;Synthetic Materials Sales;building cleaning service;Sales of new catalytic materials and additives;Eco-environmental material sales;Bio-organic fertilizer research and development;Environmental protection special equipment sales(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Health Consulting Services(Does not include medical services);Remote Health Management Services;Smart home consumer device sales;Manufacturing of Smart Home Consumer Devices;Refrigeration,Air Conditioning Equipment Manufacturing;Professional cleaning,to clean,Disinfection service;Synthetic Materials Sales;building cleaning service;Sales of new catalytic materials and additives;Eco-environmental material sales;Bio-organic fertilizer research and development;Environmental protection special equipment sales;Disinfectant sales(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

InfaCare Pharmaceutical develops pharmaceuticals for the neonatal and pediatric patient population. They provide medicines to address unmet patient needs. Their areas of focus include autoimmune and rare diseases in specialty areas including neurology, rheumatology, nephrology, pulmonology, immunotherapy, neonatal respiratory critical care therapies, and gastrointestinal products.